Axsome: SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT) Should Contact Grabar Law Office Today

PHILADELPHIA, April 14, 2025 (GLOBE NEWSWIRE) --Axsome Therapeutics Inc. (NASDAQ:AXSM) Class Action Survives Motion to Dismiss:Grabar Law Office is investigating claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ:AXSM) as an underlying securities fraud class action has survived a motion to dismiss the complaint.If you are a current Axsome (NASDAQ:AXSM) shareholder who purchased Axsome shares prior to May 10, 2021, and still hold shares today, you may be able to seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/axsome-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085WHY?: An underlying securities fraud class action complaint alleges that Axsome Therapeutics (NASDAQ:AXSM), via certain of its officers, made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.On March 31, 2025, the Court issued an Order denying Axsome's Motion to Dismiss. The Court determined that the operative complaint sufficiently pleads material misrepresentations or omissions regarding two categories of statements: (1) Defendants' statements that the manufacturing facility and suppliers for AXS-07 were not experiencing problems and (2) Defendants' statements about AXS-07's NDA. WHAT YOU CAN DO NOW: If you purchased Axsome Therapeutics (NASDAQ:AXSM) prior to May 10, 2021 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/axsome-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You may be able to seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $AXSM #AxsomeDriven Brands Holdings, Inc. (NASDAQ:DRVN) Class Action Survives Motion to Dismiss:A securities fraud class action complaint against Driven Brands Holdings, Inc. (NASDAQ:DRVN) has ...Full story available on Benzinga.com